Targeted Alpha Therapy with Astatine-211

>>>> Remote meeting <<<<
2.13.0.02.13.0.0
Targeted Alpha Therapy (TAT) has the potential to become a curative and less toxic alternative and/or compliment to today’s standard cancer treatment. 
The method, which incorporates alpha emitting radionuclides, such as At-211, coupled to cancer-targeting biological molecules like antibodies, peptides, or small molecules, can eliminate cancer cells in tumours and metastases, without causing significant damage to a patient’s healthy cells or tissues. 
The pharmaceuticals used for TAT act like microscopic, guided missiles. The biological vector is the missile that carries a payload (the alpha emitter) directly toward a specific target (the cancer cell type to be eliminated). The alpha emitter kills the cancer cells by emitting alpha particles with a high energy and short path length. The high energy particles cause double stranded breakage to the cancer cells’ DNA, effectively killing the cells, whilst the particles’ short path length ensures that damage to surrounding healthy cells and tissue is minimised. The result is an internal, highly targeted and less toxic local irradiation of cancer cells.
The lecture will be split in two parts; the first part on the scientific aspects of TAT will be given by Emma Aneheim, and the second part, that will be focused on Atley and the commercial aspects, will be led by Milton Lönnroth.
2.13.0.0